Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

William C.N. Dunlop, Alexandra Staufer, Pierre Lévy and Guy J. Edwards
Additional contact information
Pierre Lévy: LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres

Post-Print from HAL

Keywords: Drug costs; Drug industry/economics; Drug industry/organization & administration; Risk sharing; financial; Innovative pricing agreements; Managed entry agreements (search for similar items in EconPapers)
Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Published in Health Policy, 2018, 122 (5), ⟨10.1016/j.healthpol.2018.02.008⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02274079

DOI: 10.1016/j.healthpol.2018.02.008

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().